FRANKFURT, Germany, July 10, 2024--(BUSINESS WIRE)--Merz Therapeutics announces today ... approved in the U.S. and commercialized as FAMPYRA in the European Union and other territories throughout ...

and FAMPYRA for $185 million. Merz Therapeutics, a leader in the field of neurotoxins, is a business of the global family-owned company Merz, headquartered in Frankfurt am Main, Germany.

Merz Therapeutics has successfully acquired Acorda’s Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) after the latter went bankrupt earlier this year. The sale was via a ...